Companies › AbClon
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AT101 Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy | CD19 | Phase 1 | B-cell Non Hodgkin Lymphoma | Mar 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05338931 | AT101 | Phase 1 | B-cell Non Hodgkin Lymphoma | Oncology | Mar 2030 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.